Showing results (811-820 of 863) with videos related to

Sort By:
Pageof 87
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2008
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancerD Cunningham, B Sirohi, A Pluzanska, et al.
Journal of Health Psychology|January 16, 2014
Effectiveness of a Screening and Brief Intervention protocol for heavy drinkers in dental practice: A cluster-randomized trialJames Alan Neff, Michelle L Kelley, Scott T Walters, et al.
British Journal of Cancer|July 24, 2015
Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancerJ Rees, C N Hurt, S Gollins, et al.
British Journal of Cancer|March 6, 2015
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerT J Price, M A Bruhn, C K Lee, et al.
BMC Health Services Research|May 15, 2025
Evaluating a train-the-trainer approach for implementing obstetric life support in diverse healthcare contexts throughout Arizona: a mixed methods protocolShayna D Cunningham, Rogie Royce Carandang, Laurie S Wood, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2016
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinomaS-E Al-Batran, E Van Cutsem, S C Oh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancerA Webb, D Cunningham, J H Scarffe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 14, 2018
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trialsM J Maurer, T M Habermann, Q Shi, et al.
ESMO Open|March 22, 2024
Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGEE Cartwright, S Slater, C Saffery, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 30, 2017
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trialM Gleeson, N Counsell, D Cunningham, et al.
Pageof 87